A class of diabetes medications known as SGLT2 inhibitors can increase the risk of a serious condition called diabetic ketoacidosis (DKA), a leading body of diabetes consultants in the United Kingdom said in a recently released position statement. The Association of British Clinical Diabetologists (ABCD) warned physicians to exercise caution when prescribing SGLT2 inhibitors to diabetic patients because the medication elevates their risk of developing DKA, a life threatening condition in which too much acid builds up in the blood. SGLT2 inhibitors, which include the brand name drugs Invokana and Invokamet, are indicated for patients with type 2 diabetes, however they have ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.